UPDATE 2-AstraZeneca wins U.S. approval for longer use of blood thinner
September 04, 2015 at 04:21 AM EDT
* AstraZeneca targeting Brilinta sales of $3.5 bln by 2023 (Adds executive and analyst comments on Brilinta growth)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.